Many skin conditions are more than a localized problem. Patients with eczema, psoriasis, vitiligo or alopecia often struggle with chronic inflammation and therapy resistance. New insights show that the gut-skin axis plays a central role in this: gut dysbiosis affects immune activation, oxidative stress and skin barrier function.

Multi-omics makes this dialogue visible and provides dermatologists with additional biomarkers to better understand complex skin diseases and provide personalized treatment.

The clinical problem

• Psoriasis & eczema: often associated with intestinal dysbiosis and reduced production of AHR ligands (indole derivatives) that dampen inflammation(Jimenez-Sanchez et al., Gut 2025).
• Vitiligo: patients show decreased microbial diversity and specific abnormalities in metabolites affecting melanocyte function(Yuan et al., Front Immunol 2025; Dou et al., Front Microbiol 2025).
• Alopecia & post-COVID skin disorders: postviral dysbiosis can trigger persistent skin inflammation(Guermazi et al., COVID 2025).
• Nigro et al, Arch Dermatol Res 2025: systematic review confirms that gut and skin microbiome are disrupted in vitiligo.

Multi-omics insights into the gut-skin axis

1. Dysbiosis and inflammation
   - Intestinal flora affects Th17/Treg balance; imbalance fuels psoriasis and eczema(Pai et al., IJDVL 2025).
2. Metabolites & skin pigmentation
   - Liu & Liu, Biosci Microbiota 2025: certain bacterial metabolites correlate negatively with vitiligo progression.
3. Immune crosstalk via AHR
   - Jimenez-Sanchez et al., 2025: reduced activation of AhR (aryl hydrocarbon receptor) potentiates skin inflammation.
4. Vitiligo-specific markers
   - Dou et al., 2025: multi-omics identified microbial biomarkers that distinguish vitiligo patients from healthy controls.
5. Post-COVID dysbiosis and skin
   - Guermazi et al., 2025: Post-COVID gut dysbiosis can trigger eczema and vitiligo via immune crosstalk.

Innovative solutions for the clinic

1. Skin-Microbiome Signature
   - My InnerSelfie analyzes DNA, microbiome profiles and metabolites that influence skin inflammation and pigmentation.
2. Vitiligo Biomarker Panel
   - Identifies gut-driven metabolites that regulate melanocytes.
3. Leaky Gut & Eczema Scan
   - Objective markers for intestinal permeability and inflammatory pathways that fuel skin inflammation.
4. Therapy response personalized
   - Multi-omics may explain why patients respond differently to biologicals or topicals.

Why My InnerSelfie is unique

• Multi-omics integration: DNA, metabolites and microbiome in one profile.
• Crosstalk focus: visualizing how gut-skin interactions affect inflammation, pigmentation and repair.
• Preventive precision: identify risks of flare-ups or therapy resistance early.
• Additional tool for the physician: decisions remain in the hands of the dermatologist; we provide additional layers of evidence.
• Tomorrow's care: innovative, preventive and always customized. Innovation of today becomes the standard of tomorrow - safe and scientifically based.

Key insights

• Eczema, psoriasis and vitiligo are partly driven by gut-skin crosstalk.
• Multi-omics reveals immune and metabolite profiles that remain invisible in classical diagnostics.
• My InnerSelfie helps dermatologists personalize therapy and develop preventive strategies.

Scientific references

• Yuan C, Liu L, Zeng D, et al. Gut microbiota metabolites and vitiligo via the gut-skin axis. Front Immunol. 2025.
• Jimenez-Sanchez M, Celiberto LS, Yang H, et al. Gut-skin axis in psoriasis and dermatitis via AHR ligands. Gut. 2025.
• Nigro A, Osman A, Suryadevara P, et al. Systematic review: gut and skin microbiome in vitiligo. Arch Dermatol Res. 2025.
• Dou Y, Niu Y, Shen H, et al. Disease-specific gut microbial markers in vitiligo. Front Microbiol. 2025.
• Kumar S, Mahajan S, Kale D, et al. Gut microbiome in vitiligo patients (India cohort). BMC Microbiol. 2024.
• Pai VV, Sarath AP, Kerkar Z. Gut microbiome in dermatology. IJDVL. 2025.
• Liu X, Liu J. Vitiligo and gut dysbiosis. Biosci Microbiota Food Health. 2025.
• Guermazi D, Guermazi E. Post-COVID gut dysbiosis and skin disorders. COVID. 2025.